Men and women aged 18 years or older who have advanced breast cancer due to a BRCA1 or BRCA2 gene mutation are invited to see if they may qualify for the Brocade Study. The purpose of this medical research study is to determine the safety and effectiveness of the investigational medication Veliparib (a PARP-inhibitor) in combination with chemotherapy in patients with metastatic or locally recurrent breast cancer.
Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive chemotherapy in combination with either the investigational medication Veliparib or an inactive placebo, BRCA-related testing, study-related medical exams, and lab tests at no charge. Compensation for time and travel may also be available.